Yahoo Web Search

Search results

1. • BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

     Digital Journal· 3 days ago

     “We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate...immunotherapy has shown survival and clinical benefit in patients ...

2. • 

     AI cancer screening programs are booming, but you'll likely have to pay for them yourself

     CNBC· 18 hours ago

     The FDA has approved nearly 600 radiology AI program since 2019, but most aren't covered by Medicare...

3. • How to Maximize the Benefits of Green Tea

     Mercola· 2 hours ago

     If you've ever found it curious how devoted the English, Chinese and East Indians seem to be about keeping their tea times (not tee times), you might be interested to know that it often goes ...

4. • 

     Those lost to Agent Orange, Camp Lejeune exposure honored in Peabody

     The Salem News· 3 days ago

     Ramos underwent radiation and a lumpectomy, but was diagnosed again in 2007 and 2009. She had...

5. • 

     Health Care Roundup: Market Talk

     The Wall Street Journal· 1 day ago

     Data on an obesity drug in development is encouraging, but it needs to be differentiated from other treatments on the market, Berenberg says. Likewise,...

6. • 

     Gilead pays $20M to join Cartography's next-gen cancer medicine expedition

     FierceBiotech· 3 days ago

     Gilead Sciences is drawing up $20 million cash to partner with Cartography Biosciences and navigate ...

7. • 

     N.J. Gov. Murphy visits Black-owned cannabis cultivator - WHYY

     WHYY· 4 hours ago

     “I use cannabis to survive and pay bills,” said Nicolas, a first-generation Haitian American who...

8. • 

     Gilead and Cartography enter deal to develop cancer therapies

     Pharmaceutical Technology via Yahoo Finance· 2 days ago

     Cartography looks forward to working with Gilead and leveraging the team’s expertise in oncology and...

9. • ...Elacestrant (ORSERDU®) in Patients with ER+, HER2- MetastaticBreast Cancer (mBC) at the ASCO 2024...

     Benzinga· 7 days ago

     The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.Updated results from the ELECTRA study, evaluating elacestrant in

10. • BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

      Digital Journal· 7 days ago

      83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression ...